Skip to main content
Erschienen in: The Indian Journal of Pediatrics 3/2015

01.03.2015 | EDITORIAL COMMENTARY

Hepatitis B and C Infections in Multitransfused Thalassemic Patients

verfasst von: Ved Prakash Choudhry

Erschienen in: Indian Journal of Pediatrics | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Excerpt

Transfusion transmitted infections (TTI) are major causes of morbidity and mortality among multi-transfused patients such as thalassemics, hemophilics, patients on hemodialysis etc. Article by Sabat et al. in this issue of the Journal is of great concern for developing countries, including India where the prevalence of antibodies to hepatitis C, HBsAg, anti HBs and anti HBc was observed in 3.4, 0.5, 30.4 and 21.8% of 174 thalassemic cases respectively [1]. Higher prevalence with increasing age and blood transfusion is well understood. However, the major concern is of occult hepatitis B infection (OHBV) in 50% cases with positive anti HBc. Higher incidence of OHBV has been reported earlier [2, 3]. Presence of OHBV in patients with liver cirrhosis is still higher [4, 5]. Presence of HBV DNA in over 16% anti HBs and anti HBc positive patients is indicative of continued viral replication, which may consequently lead to development of liver cirrhosis or hepatocellular carcinoma [1]. …
Literatur
2.
Zurück zum Zitat Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, et al. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang. 2003;84:292–9.CrossRefPubMed Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, et al. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang. 2003;84:292–9.CrossRefPubMed
3.
Zurück zum Zitat Arbabadi MK, Ahmadabadi BN, Daredor HY, Kennedy D. Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients. Hepat Mon. 2012;12:315–9.CrossRef Arbabadi MK, Ahmadabadi BN, Daredor HY, Kennedy D. Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients. Hepat Mon. 2012;12:315–9.CrossRef
4.
Zurück zum Zitat Saravanan S, Madhavan V, Murugavel KG, Balakrishnan P, Solomon SS, Subashini D, et al. Occult hepatitis B virus infection in a cohort of liver disease patients with chronic hepatitis C: a significant association of HCV genotype 1b in south India. J Gastroenterol Hepatol Res. 2013;2:692–5. Saravanan S, Madhavan V, Murugavel KG, Balakrishnan P, Solomon SS, Subashini D, et al. Occult hepatitis B virus infection in a cohort of liver disease patients with chronic hepatitis C: a significant association of HCV genotype 1b in south India. J Gastroenterol Hepatol Res. 2013;2:692–5.
5.
Zurück zum Zitat Agarwal N, Naik S, Aggarwal R, Singh H, Somani SK, Kini D, et al. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. Indian J Gastroenterol. 2003;22:127–31.PubMed Agarwal N, Naik S, Aggarwal R, Singh H, Somani SK, Kini D, et al. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. Indian J Gastroenterol. 2003;22:127–31.PubMed
6.
Zurück zum Zitat Choudhry VP, Acharya SK. Hepatitis B, C & D viral markers in multitransfused thalassemic children: long term complications and present management. Indian J Pediatr. 1995;62:655–68.CrossRefPubMed Choudhry VP, Acharya SK. Hepatitis B, C & D viral markers in multitransfused thalassemic children: long term complications and present management. Indian J Pediatr. 1995;62:655–68.CrossRefPubMed
7.
Zurück zum Zitat Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV infection among thalassemia patients in eastern mediterranean countries: a quantitative review of literature. Iran Red Crescent Med J. 2010;12:365–76. Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV infection among thalassemia patients in eastern mediterranean countries: a quantitative review of literature. Iran Red Crescent Med J. 2010;12:365–76.
8.
Zurück zum Zitat Zarina AL, Norazlin KN, Hamidah A, Aziz DA, Zulkifli SZ, Jamal R. Spectrum of infections in splenectomised thalassaemia patients. Med J Malaysia. 2010;65:284–6. Zarina AL, Norazlin KN, Hamidah A, Aziz DA, Zulkifli SZ, Jamal R. Spectrum of infections in splenectomised thalassaemia patients. Med J Malaysia. 2010;65:284–6.
9.
Zurück zum Zitat Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.PubMed Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.PubMed
10.
Zurück zum Zitat Chern JP, Su S, Lin KH, Chang SH, Lu MY, Jou ST, et al. Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer. 2007;48:550–4.CrossRefPubMed Chern JP, Su S, Lin KH, Chang SH, Lu MY, Jou ST, et al. Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer. 2007;48:550–4.CrossRefPubMed
11.
Zurück zum Zitat Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445–50.CrossRefPubMed Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445–50.CrossRefPubMed
12.
Zurück zum Zitat Asadov CD. Immunologic abnormalities in β-thalassemia. J Blood Disord Transf. 2014;5:224. Asadov CD. Immunologic abnormalities in β-thalassemia. J Blood Disord Transf. 2014;5:224.
13.
Zurück zum Zitat Bekaroğlu MG, Arslan BA. Natural killer (NK) cells in β thalassemia major patients. JSM Biotechnol Bioeng. 2014;2:1040. Bekaroğlu MG, Arslan BA. Natural killer (NK) cells in β thalassemia major patients. JSM Biotechnol Bioeng. 2014;2:1040.
14.
Zurück zum Zitat Javad G, Saeid A, Mohammadmehdi N. Thalassemia and immune system dysfunction-review article. Int J Curr Res. 2011;3:105–8. Javad G, Saeid A, Mohammadmehdi N. Thalassemia and immune system dysfunction-review article. Int J Curr Res. 2011;3:105–8.
15.
Zurück zum Zitat Khakhkhar V, Joshi PJ. HBsAg seropositivity among multitransfused thalassemic children. Indian J Pathol Microbiol. 2006;49:516–8.PubMed Khakhkhar V, Joshi PJ. HBsAg seropositivity among multitransfused thalassemic children. Indian J Pathol Microbiol. 2006;49:516–8.PubMed
16.
Zurück zum Zitat Sood A, Midha V, Sood N, Awasthi G. Prevalence of anti-HCV antibodies among family contacts of hepatitis C virus-infected patients. Indian J Gastroenterol. 2002;21:185–7.PubMed Sood A, Midha V, Sood N, Awasthi G. Prevalence of anti-HCV antibodies among family contacts of hepatitis C virus-infected patients. Indian J Gastroenterol. 2002;21:185–7.PubMed
17.
Zurück zum Zitat Akhtar S, Moatter T, Azam SI, Rahbar MH, Adil S. Prevalence and risk factors for intrafamilial transmission of hepatitis C virus in Karachi. Pakistan J Viral Hepat. 2002;9:309–14.CrossRef Akhtar S, Moatter T, Azam SI, Rahbar MH, Adil S. Prevalence and risk factors for intrafamilial transmission of hepatitis C virus in Karachi. Pakistan J Viral Hepat. 2002;9:309–14.CrossRef
18.
Zurück zum Zitat Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, et al; Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116:2875–83. Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, et al; Society for the Study of Thalassemia and Haemoglobinopathies; Italian Association for the Study of the Liver. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood. 2010;116:2875–83.
19.
Zurück zum Zitat Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006;30:119–24.CrossRefPubMed Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006;30:119–24.CrossRefPubMed
20.
Zurück zum Zitat European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis. J Hepatol. 2009;50:227–42.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis. J Hepatol. 2009;50:227–42.CrossRef
21.
Zurück zum Zitat Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111–24.CrossRefPubMed Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111–24.CrossRefPubMed
Metadaten
Titel
Hepatitis B and C Infections in Multitransfused Thalassemic Patients
verfasst von
Ved Prakash Choudhry
Publikationsdatum
01.03.2015
Verlag
Springer India
Erschienen in
Indian Journal of Pediatrics / Ausgabe 3/2015
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-014-1676-0

Weitere Artikel der Ausgabe 3/2015

The Indian Journal of Pediatrics 3/2015 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.